Title : Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences.

Pub. Date : 2022 Apr 26

PMID : 35445633






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Osimertinib, almonertinib and furmonertinib are third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) approved for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib epidermal growth factor receptor Homo sapiens
2 Osimertinib, almonertinib and furmonertinib are third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) approved for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. osimertinib epidermal growth factor receptor Homo sapiens